Liraglutide: Weight Loss, Dosing, & Safety Info
Découvrez les bienfaits du Liraglutide, un agoniste du récepteur GLP-1 pour la perte de poids et le diabète, désormais disponible sous forme générique. Renseignez-vous sur le dosage, les effets et les résultats des recherches.
Aperçu
Liraglutide a été le premier agoniste du récepteur GLP-1 approuvé pour le traitement de l'obésité. Il nécessite une injection quotidienne, mais bénéficie de plus de 15 ans de données de sécurité et est désormais disponible en générique.
Key Information
Mechanism
Agoniste du récepteur GLP-1 présentant une demi-vie de 13 heures nécessitant une administration quotidienne. Produit des pics et des creux de concentrations médicamenteuses, contrairement aux formulations hebdomadaires.
Benefits
- Perte de poids de 6,4-8,0 %
- Données de sécurité sur plus de 15 ans
- Générique disponible
- Approbation pédiatrique
Side Effects
- Nausées (39%)
- Diarrhée (21%)
- Vomissements (16%)
- Injection quotidienne requise
Contraindications
- Medullary thyroid carcinoma
- MEN2 syndrome
Evidence Summary
Essais SCALE (5 000 participants), essai LEADER (9 340 patients, réduction de 13 % des MACE).
Research
Les essais SCALE ont montré une perte de poids de 6,4 à 8,0 %. L'essai LEADER a montré une réduction de 13 % des MACE chez les patients DT2.
View ResearchSafety
Plus de 15 ans de données de sécurité post-commercialisation. Avertissement encadré de même classe concernant les tumeurs des cellules C thyroïdiennes.
Liraglutide: Weight Loss, Dosing, & Safety Info
Liraglutide was the first GLP-1 receptor agonist approved for obesity. It requires daily injection but has 15+ years of safety data and is now available as a generic.
Key Information
- Also known as: Saxenda; Victoza
- Sequence: GLP-1(7-37) with C16 fatty acid
- CAS number: 204656-20-2
- Molecular formula: C172H261N43O53
- Half-life: 13 hours
- Administration: subcutaneous injection
- Dose range: 0.6-3.0 mg daily
- Price range: $1.5–$15.0/mg
- Storage: refrigerated 2-8C
- Reconstitution: pre-filled pen, no reconstitution needed
- US status: FDA-approved (generic available)
- Legal status: FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.
- Research papers: 5 indexed
Mechanism
GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.
Benefits
- 6.4-8.0% weight loss
- 15+ years safety data
- Generic available
- Pediatric approval
Side Effects
- Nausea (39%)
- Diarrhea (21%)
- Vomiting (16%)
- Daily injection required
Contraindications
- Medullary thyroid carcinoma
- MEN2 syndrome
Evidence Summary
SCALE trials (5,000 participants), LEADER trial (9,340 patients, 13% MACE reduction).
Research
SCALE trials showed 6.4-8.0% weight loss. LEADER trial showed 13% MACE reduction in T2D patients. View the research papers indexed on our research page.
Safety
15+ years post-marketing safety data. Same class boxed warning for thyroid C-cell tumors.
Legal Status
FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.
Frequently Asked Questions About Liraglutide
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist also known as Saxenda and Victoza. It is a first-gen GLP-1 agonist requiring daily injection, now available as a generic. It is studied for its potential therapeutic applications and is available from various research chemical vendors.
How does Liraglutide work?
GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.
What is the recommended dosage for Liraglutide?
The commonly studied dosage range for Liraglutide is 0.6-3.0 mg daily. Dosage protocols vary based on research objectives. Always consult published studies and start with conservative amounts. Liraglutide should only be used in controlled research settings.
Where can I buy Liraglutide?
PepsReview indexes Liraglutide pricing from multiple vendors. Check the Vendors tab above for a price comparison table showing cost per milligram, purity, COA status, and stock availability. Vendor reviews from real users are available on each vendor's profile page.
Is Liraglutide legal?
US regulatory status: FDA-approved (generic available). FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.
What are the side effects of Liraglutide?
Reported side effects include: nausea (39%), diarrhea (21%), vomiting (16%), daily injection required. Always review safety data and published studies before use.
Key Research Papers on Liraglutide
The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide. Each paper links to a short summary with key findings, study design, and publication data.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
- Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial — N Engl J Med, 2025 (200 citations)
Related Weight Loss / Metabolic Peptides
Other peptides in the weight loss / metabolic category that may be of interest for comparative research:
- Semaglutide — GLP-1 receptor agonist for weight loss and diabetes management
- Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
- Retatrutide — Triple agonist (GLP-1/GIP/Glucagon), next-gen weight loss
- Survodutide — Dual GLP-1/glucagon agonist in development
- AOD-9604 — Modified growth hormone fragment for fat burning
Key Research Papers on Liraglutide: Weight Loss, Dosing, & Safety Info
The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide: Weight Loss, Dosing, & Safety Info. Each paper links to a detailed summary with key findings, study design, and publication metadata.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
- Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial — N Engl J Med, 2025 (200 citations)
Related Weight loss / Metabolic Peptides
Other peptides in the weight loss / metabolic category that may be of interest for comparative research:
No vendor prices yet
We don't have pricing data for this peptide yet.
Write a Review
Login to write a review
You need an account to share your experience with Liraglutide: Weight Loss, Dosing, & Safety Info.
S'inscrireRating Breakdown
Based on 2 avis.
Avis
Used liraglutide for 8 months. Lost about 10 lbs. It works but weekly options like semaglutide are much more convenient. Good safety profile though - 15 years of data is reassuring.
Lost 14 lbs over 6 months. Works well but having to inject daily is a hassle compared to weekly options. Nausea was manageable. Good option if you want something well-studied with long safety data.